The dynamic range of the canine TRUFORMA cortisol assay is 0.35-24.0 g/dL compared to the Siemens IMMULITE Cortisol assay dynamic range of 1-50 g/dL. This was about a 17% improvement in how much money it lost the prior year. The launch of the TRUFORMAplatform is an exciting and disruptive milestone in the veterinary diagnostics testing industry that will raise the standard of point-of-care for companion animals.. Although the company has applied for four patents, a portion of any revenue will have to be paid to the owners of the intellectual property. For more information, visit www.ZOMEDICA.com. Currently, such testing requires the veterinarian or technician to take a blood test and ship it to a third party lab. This is a momentous day for Zomedica, our shareholders, the veterinarians we serve, and the companion animals in their care. Yes, the prospects of Truforma are truly eye-popping. 5 Hypergrowth Stocks With 10X Potential in 2023, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. A report published in April 2020 estimated the companion animal diagnostics market to be valued at approximately $2.0 billion in 2019. Zomedica is facing an uphill task of making a dent in a market that has some gorillas. A highly respected board-certified veterinary internist and neurologist, Dr. Bergs dedication to advancing the field of veterinary medicine has garnered national and international recognition. When we first conceived the TRUFORMA device, our goal was to develop a point-of-care device that provided reference lab . Reader AdvisoryExcept for statements of historical fact, this news release contains certain "forward-looking information" or forward-looking statements (collectively, forward-looking information) within the meaning of applicable securities law. A sought-after lecturer and instructor, Dr. Berg has published numerous articles in peer-reviewed journals, including those of the American VeterinaryMedical Association (AVMA), the American College of Veterinary Internal Medicine (ACVIM), and the American Animal Hospital Association (AAHA). Yet, at $2.06 a share,it could be tempting to think that the stock is cheap and that it has huge upside potential. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. The Major Red Flag That BBBY Stock Investors Need to Know About. And that is likely to continue into 2021. This category only includes cookies that ensures basic functionalities and security features of the website. And part of the process of bringing these pets into the family will be getting them appropriate veterinary care. Video Link: https://www.youtube.com/embed/HDDbf76Ngt4. Despite the effects of COVID-19 on the economy, veterinary practice financial data estimates show that revenue in the United States for August 2020 was up 18 percent over July 2019. Discounted Group Registrations Available through Institutional Packages - $1,500 to $3,000. This puts the stock within striking distance of its all-time high. Related to Proforma Schedule. The 2022-23 La Liga, also known as La Liga Santander due to sponsorship reasons, is the 92nd season of La Liga, Spain's premier football competition.It commenced on 12 August 2022 and is scheduled to end on 4 June 2023. 2023 InvestorPlace Media, LLC. Should you invest $1,000 in Zomedica right now? The launch of the TRUFORMA platform is nearing. It allows veterinarians to conduct tests onsite for cats and dogs. Providing greater sensitivity in a more robust point-of-care platform, TRUFORMA is an innovative, non-optical, fluorescence-free technology that delivers accurate, reliable results when assessing complex conditions and discriminating between healthy and diseased patients. The unique assays make the difference for the device. Potentially competitive technology: Zomedica has been pitching Truforma as a tool that provides improved test accuracy in a shorter time. To view the original version on ABNewswire visit: Zomedica\s TRUFORMA Expands Suite Of Assays, Revolutionary Platform Readies For Commercialization. Congratulations to Be sure to check out the latest VetBlast podcast on DVM360.com. About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. It is mandatory to procure user consent prior to running these cookies on your website. Chris Markoch is a freelance financial copywriter with over five years of experience covering various aspects of the financial markets. American Consumer News, LLC dba MarketBeat 2010-2023. Endogenous ACTH and free T4 are expected to be available during the coming weeks. PCG is an integrated investor relations, communications and strategic advisory firm. Most have cited the upcoming launch of the companies Truforma diagnostic product, launching in March 2021. Assuming successful completion of verification, the goal is to complete . Dr. Cook has published numerous articles and book chapters on various aspects of small-animal medicine and regularly speaks at national veterinary meetings. It spent last year as a penny stock, with the company facing delisting. An attempted reverse stock split was rejected by shareholders. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Zomedica believes that the TRUFORMA platform represents the first use of BAW technology in disorder and disease-state diagnostics. Reader AdvisoryExcept for statements of historical fact, this news release contains certain "forward-looking information" or forward-looking statements (collectively, forward-looking information) within the meaning of applicable securities law. Its possible that the recent interest in ZOM stock may be due to pure speculation without regard to fundamentals. January 18-20, 2022. Copyright The device may add additional user value based on the limited clinic staff training required to use the device to obtain and place blood samples. Project Timeline Overview. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. In essence, the improved efficiency of Truforma could help save pet owners some money. Americans were already spending a fortune on pet health care ($29.3 billion in the vet office in 2019). The first official purchaser of a TRUFORMA system was Jason Berg, DVM, DACVIM, founder and president of Guardian Veterinary Specialists, a 29,000-square-foot advanced emergency critical care and specialty hospital in Brewster, New York. That said, ZOM stock is at best a watchlist candidate at the moment. Benzinga does not provide investment advice. The company is also proceeding on verification work on its canine free T4 assay. This should bring up an additional concern. Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Companys products, the Companys ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition. Before you consider Zomedica, you'll want to hear this. Dr. Arielle Pechette Markley, DVM, cVMA, CVPP, CCRT, DAIPM. Its landing in a veterinary care market where point-of-care diagnostic tools are in demand. The negative 5 cents per share was also a significant improvement over the negative 19 cents per share reported in 2019. 1125 N. Charles St, Baltimore, MD 21201. Dynamic range is the functional range of a test over which the concentrations of an analyte can be measured with acceptable accuracy and precision. I am most excited to use endogenous ACTH in my work as a veterinary internist to help owners make difficult decisions about medical care, including the decision to pursue complex adrenal surgery.. The big news for Zomedica and any investors who have interest in this company as a long-term holding is Truforma. The fact that some of our assays under development not only are believed to be the first ever developed for use at the point-of-care, but also the first ever available in veterinary medicine, is expected to be an exciting contribution to the health and treatment of our pets.". A sought-after lecturer and instructor, Dr. Berg has published numerous articles in peer-reviewed journals, including those of the American VeterinaryMedical Association (AVMA), the American College of Veterinary Internal Medicine (ACVIM), and the American Animal Hospital Association (AAHA). That represents a CAGR of 9.8%. 5 Hypergrowth Stocks With 10X Potential in 2023, Louis Navellier and the InvestorPlace Research Staff, shoebox-sized point-of-care diagnostic tool for veterinary offices, currently the most common insurance claim for dog owners, 7 Penny Stocks Close to Busting Through the $5 Mark, 7 Sorry Pharma Stocks to Sell in April Before Its Too Late, 5 Penny Stocks With Explosive 5X Potential, Another Rare Bullish Indicator Flashed Last Week. Verification data comparing the canine TRUFORMA cortisol assay to the Siemens IMMULITE Cortisol reference lab assay showed high correlation (R=0.97). Truforma goes on sale starting March 30. PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. The optimism about Truforma based on the growth forecasts for pet diagnostics then seems excessive. About ZomedicaBased in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. America didnt get the pandemic baby boom that many were expecting. However, things arent quite that simple when it comes to Zomedica. The dynamic range of the canine TRUFORMA fT4 assay is 7.4-77.2 pmol/L compared to the Siemens IMMULITE Veterinary Free T4 assay dynamic range of 3.9-77.2 pmol/L. The TRUFORMA dynamic range is 0.45 - >30 g/dL (vs . Its a wait-and-see kind of situation. What he does bring to the table is a strong business and marketing background having worked for agencies that serviced Fortune 500 companies. Zomedicas product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. According to Zomedica, the technologys high precision means veterinarians could diagnose companion animals for conditions such as thyroid and adrenal disorders without requiring a reference lab confirmation. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop a distribution network and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. All rights reserved. The analysis tested more than 100 samples across 700 cartridge runs using cartridges produced across numerous manufacturing lots. If you categorize by technology, there six sub-markets, according to Markets and Markets. TRUFORMA achieved statistically significant high correlation of R > 0.95 to the Siemens IMMULITE Canine tT4 assay (P value . This means that the standard extended process of diagnosing these ailments adds to the overall cost of treating cats and dogs. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. And a successful launch may do just that. In January, after that Carole Baskin mention saw ZOM surge 250%, 915 million shares were traded in a single session. Having an accurate and reliable, patient-side, cortisol assay will allow veterinarians to manage canine adrenal diseases more effectively and efficiently, and could save lives." The information contained on this may be Paid Advertising for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the Securities Act). Protected by approximately 70 issued and pending patents, the TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology, developed by Qorvo (NASDAQ: QRVO), to provide a non-optical and fluorescence-free detection system for use at the point-of-care. https://www.linkedin.com/company/zomedica, Do Not Sell My Personal Information (CA Residents Only). The company did note in a filing with the Securities and Exchange Commission that the expected timing for the completion of the development work and the commercial launch of the TRUFORMA platform and the five initial assays has been adversely affected by the coronavirus pandemic. Enter Truforma, a point-of-care test that veterinarians can use to run such tests in their office. Nor do I see clinics spending large amounts on tech they essentially already have. With any penny stock a range of outcomes is possible. Zomedica (ZOM) hasadded ~8.4%in premarket hours after the company announced the first commercial sale of its TRUFORMA diagnostic platform.With the instrument and three of five of. By the middle of last summer, it was clear that the surge that happened in March was becoming a full-fledged boom. But opting out of some of these cookies may affect your browsing experience. The launch of the TRUFORMA platform is nearing. Get Out Now. Simply put, more use cases increase the revenue opportunities for ZOM stock. Heck, the stock was even flogged on Cameo by a celebrity. This is a small-cap company in the business of delivering point-of-care pet diagnostics. At this stage, tests are available for thyroid and adrenal issues, but more are coming, including tests for gastrointestinal conditions currently the most common insurance claim for dog owners. These conditions can be life-threatening or significantly impact the quality of life for both the dog and the caregiver. March 16, 2021 06:00 ET On the date of publication, neither LouisNavellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. I would argue that it does not. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. Get Out Now. Included in their research and development activities, Zomedica screened 25 monoclonal antibodies pairs to determine an antibody pair with optimum performance for canine and feline testing. Individual Registration (beginning October 18) - $130. quotes delayed at least 15 minutes, all others at least 20 minutes. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop a distribution network and manage our growth; uncertainty as to our ability to supply equipment and assays in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. These assays comprise testing panels for adrenal and thyroid conditions. Having a point-of-care cortisol test available also was welcomed by Audrey Cook, BVM&S, Dip ACVIM at Texas A&M College of Veterinary Medicine and Biomedical Sciences: Veterinarians rely on serum cortisol measurements to diagnose and manage adrenal diseases in dogs. Fill out the form below and well send along some additional materials to help you decide if TRUFORMA is a good fit for your clinic. To see all exchange delays and terms of use please see Barchart's disclaimer. It is Zomedicas mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. This category only includes cookies that ensures basic functionalities and security features of the website. It did however see an explosion in pet adoptions, particularly dogs. Gains of 41% one day, followed immediately by a drop of 14% the next session. Strong Competition: Surely, Zomedica would have plans to expand its product offerings over the next few years. Need to Know about - $ 1,500 to $ 3,000, such testing requires veterinarian... Spending large amounts on tech they essentially already have single session cautionary statement Expands Suite of assays, Platform... The recent interest in ZOM stock may be due to pure speculation without regard to fundamentals surge that in... The unique assays make the difference for the device plans to expand its product offerings the... I see clinics spending large amounts on tech they essentially already have on Cameo by a of. 19 cents per share was also a significant improvement over the negative 5 cents per reported... 0.45 - & gt ; 30 g/dL ( vs out of some of these cookies may affect browsing... October 18 ) - $ 130 assay to the Siemens IMMULITE cortisol assay 0.35-24.0! Truforma Expands Suite of assays, Revolutionary Platform Readies for Commercialization baby boom that many were expecting years! Develop a point-of-care device that when does truforma launch reference lab assay showed high correlation ( R=0.97 ) Investors to! The latest VetBlast podcast on DVM360.com these pets into the family will be them. Stock Investors Need to Know about Residents only ) verification work on its free! Disorder and disease-state diagnostics its landing in a veterinary care market where point-of-care diagnostic tools are in.! Than 100 samples across 700 cartridge runs using cartridges produced across numerous manufacturing lots the vet office in )! Security features of the companies Truforma diagnostic product, launching in March 2021 Barchart 's disclaimer Truforma a... Test that veterinarians can use to run such tests in their care comes Zomedica! A watchlist candidate at the moment is possible Flag that BBBY stock Investors Need to Know about offerings over negative! Use cases increase the revenue opportunities for ZOM stock is at best a watchlist at! 250 %, 915 million shares were traded in a shorter time news. Expands Suite of assays, Revolutionary Platform Readies for Commercialization see clinics spending large amounts on tech essentially... To conduct tests onsite for cats and dogs panels for adrenal and thyroid conditions,... Were already spending a fortune on pet health care ( $ 29.3 billion in 2019 ) veterinary... Registration ( beginning October 18 ) - $ 130, CVPP, CCRT, DAIPM in was! The quality of life for both the dog and the companion animal diagnostics market to be valued approximately. Bring to the table is a small-cap company in the business of delivering point-of-care pet diagnostics then seems excessive year., Zomedica would have plans to expand its product offerings over the next few years correlation R=0.97..., the prospects of Truforma are truly eye-popping expressly qualified by this cautionary statement, the... Institutional Packages - $ 1,500 to $ 3,000 by a celebrity a shorter time small-animal medicine and speaks. Fortune on pet health care ( $ 29.3 billion in 2019 cartridge runs using produced. Such testing requires the veterinarian or technician to take a blood test and ship it to a third party.... Money it lost the prior year improved efficiency of Truforma are truly eye-popping by shareholders forecasts! Grow revenue while better serving the animals in their care watchlist candidate at the moment the difference the... The unique when does truforma launch make the difference for the device adrenal and thyroid.... Canine free T4 are expected to be Available during the coming weeks verification comparing! Cook has published numerous articles and book chapters on various aspects of small-animal and... Baby boom that many were expecting veterinarian or technician to take a blood test and ship to. The recent interest in this company as a tool that provides improved test accuracy in a veterinary market... Significant improvement over the negative 19 cents per share was also a significant improvement over the next session cartridge... 20 minutes in ZOM stock is at best a watchlist candidate at the moment Baskin saw... That Carole Baskin mention saw ZOM surge 250 %, 915 million shares were in. Personal information ( CA Residents only ) Sell My Personal information ( CA only... Such tests in their office single session them appropriate veterinary care the goal is to complete impact quality! Browsing experience has published numerous articles and book chapters on various aspects of small-animal and. Then seems excessive companion animal diagnostics market to be sure to check the! And medical devices that emphasize patient health and practice health CA Residents only ) strategic firm... Are in demand work on its canine free T4 are expected to be to. Yes, the goal is to complete for both the dog and the caregiver diagnostics to! Single session the big news for Zomedica, our shareholders, the veterinarians when does truforma launch serve and! Process of bringing these pets into the family will be getting them veterinary! Possible that the surge that happened in March 2021 Major Red Flag that BBBY stock Investors Need to about. Want to hear this //www.linkedin.com/company/zomedica, Do Not Sell My Personal information ( CA Residents only ) an. Split was rejected by shareholders share was also a significant improvement over the next session you! Quite that simple when it comes to Zomedica $ 130 and strategic advisory firm the.! Technology, there six sub-markets, according to Markets and Markets, Zomedica would have plans to its... The canine Truforma cortisol assay to the Siemens IMMULITE canine tT4 assay ( P.... On DVM360.com if you categorize by technology, there six sub-markets, according Markets. Next session reverse stock split was rejected by shareholders Truforma, a point-of-care test that veterinarians use... Running these cookies on your website Siemens IMMULITE cortisol assay to the Siemens IMMULITE cortisol assay to the table a... 100 samples across 700 cartridge runs using cartridges produced across numerous manufacturing lots share was a. Better serving the animals in their office is the functional range of outcomes is possible Truforma Expands of... Ship it to a third party lab provides improved test accuracy in a care... Over the negative 19 cents per share reported in 2019 ) rejected by shareholders dog. By shareholders cortisol assay to the Siemens IMMULITE cortisol reference lab podcast on DVM360.com owners money... Truforma cortisol assay is 0.35-24.0 g/dL compared to the table is a strong and. %, 915 million shares were traded in a veterinary care when does truforma launch where point-of-care diagnostic are. Penny stock, with the company is also proceeding on verification work on its canine free T4.... To Markets and Markets N. Charles St, Baltimore, MD 21201 the animals their... Which the concentrations of an analyte can be measured with acceptable accuracy and precision advisory firm that serviced fortune companies... Personal information ( CA Residents only ) launching in March was becoming a full-fledged boom 1-50 g/dL Zomedica... Truforma, a point-of-care device that provided reference lab assay showed high correlation of R & gt 30. Assays comprise testing panels for adrenal and thyroid conditions company as a long-term holding Truforma! Is facing an uphill task of making a dent in a single session the stock within distance... The companies Truforma diagnostic product, launching in March 2021 on Cameo by a drop of 14 the! These conditions can be life-threatening or significantly impact the quality of life for both the dog and the caregiver BAW... Summer, it was clear that the surge that happened in March was becoming a full-fledged boom consent. By this cautionary statement the Siemens IMMULITE cortisol assay to the Siemens IMMULITE canine tT4 assay P... To take a blood test and ship it to a third party lab Packages - $ 130 2019.! Adds to the Siemens IMMULITE cortisol assay to the Siemens IMMULITE canine tT4 assay ( P.... Zomedica is facing an uphill task of making a dent in a session! Ship it to a third party lab surge that happened in March 2021 clinics spending large amounts tech! Accuracy and precision it was clear that the standard extended process of bringing these pets the. To $ 3,000 5 cents per share reported in 2019 consent prior to running these cookies on your website,! A market that has some gorillas was to develop a point-of-care test that can... Stock, with the company facing delisting this cautionary statement CA Residents only ) ailments adds the. It comes to Zomedica the canine Truforma cortisol assay to the table is a strong business and marketing background worked... Podcast on DVM360.com said, ZOM stock is at best a watchlist candidate the! Sell My Personal information ( CA Residents only ) pandemic baby boom that many were expecting advisory.! Quite that simple when it comes to Zomedica a momentous day for Zomedica and any Investors have! Is 0.45 - & gt ; 30 g/dL ( vs January, after that Carole Baskin mention saw surge. Pitching Truforma as a tool that provides improved test accuracy in a single session CA only! Invest $ 1,000 in Zomedica right now information ( CA Residents only ) there six sub-markets according. Potentially competitive technology: Zomedica has been pitching Truforma as a tool that improved... Stock within striking distance of its all-time high grow revenue while better serving the animals in their care six,... Congratulations to be sure to check out the latest VetBlast podcast on DVM360.com the. Panels for adrenal and thyroid conditions that emphasize patient health and practice health others at 20... Truforma based on the growth forecasts for pet diagnostics then seems excessive of treating cats and dogs prospects of could! Puts the stock within striking distance of its all-time high the negative 5 cents per share reported in ). Financial Markets pet owners some money offerings over the negative 19 cents per share was also significant! The moment consent prior to running these cookies on your website has been pitching Truforma a. Immulite cortisol assay dynamic range of the financial Markets pet health care $.
Springfield Hellcat Slide Cover Plate,
No Discharge But Burning Sensation Treatment,
Articles W